Bionano Genomics Inc. (NASDAQ:BNGO) does about 23.45M shares in volume on a normal day but saw 6728271 shares change hands in Friday trading. The company now has a market cap of 87.20M USD and an enterprise value of about $85.76M. Its current market price is $0.62, marking a decrease of -1.59% compared to the previous close of $0.63. The 52 week high reached by this stock is $4.70 whilst the lowest price level in 52 weeks is $0.25. The script in recent trading has seen the stock touch a high of $0.62 and a low of $0.5915.
Bionano Genomics Inc. (BNGO) has a 20-day trading average at $0.7215 and the current price is -86.81% off the 52-week high compared with 148.00% distance from its 52-week low. The 50-day simple moving average of the closing price is $0.6464 and its 200-day simple moving average is $0.7362. If we look at the stock’s price movements over the week, volatility stands at 9.91%, which decreases to 8.26% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 42.39 to suggest the stock is neutral.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on April 08, 2020 when Oppenheimer initiated the stock to “Outperform” and issued a price target of $1.50.
The current price level is -15.07%, -3.78%, and -16.04% away from its SMA20, SMA50, and SMA200 respectively, with the BNGO price moving above the 50-day SMA on August 28. Bionano Genomics Inc. (BNGO) stock is down -3.13% over the week and -22.45% over the past month. Its price is -50.00% year-to-date and -58.11% over the past year.
The stock last released its quarterly earnings report for quarter ended 6/29/2020, with the company’s earnings per share (EPS) of -$0.09 below consensus estimates by $0. The company’s next earnings report is expected on 11/04/2020, with forecasts estimating quarterly EPS at -$0.05 and -$0.33 for whole year. BNGO’s earnings per share are forecast to grow by 83.40% this year and 39.40% over next year. Expected sales for next quarter are $3.6 million, which analysts say will come at $8 million for the current fiscal year and next year at $21.17 million. In addition, estimates put the company’s current quarterly revenue at an average of $2.12 million.
Its 12-month price target is $1.50. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $1.15, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $2.00.
Outstanding shares total 138.48M with insiders holding 10.41% of the shares and institutional holders owning 11.26% of the company’s common stock. The company has a return on investment of -114.90%. Price to book ratio is 10.33 and price to sales ratio is 10.38.
According to a U.S. Securities and Exchange Commission filing, Vanguard Extended Market Index Fu has reduced its position in Bionano Genomics Inc. (BNGO) to 354,773 shares, mirroring a recent drop by 0.00%. Vanguard Extended Market Index Fu dumped 0.0 shares of Bionano Genomics Inc. common stock bringing its total worth to about $0.28 million at the end of recent close, SEC documents show. Vanguard Extended Market Index Fu isn’t the only investment manager who changed stakes and is followed by Fidelity Comwlth Tr – Nasdaq Co, which added 604.0 shares to end up with 210,047 shares worth $0.17 million. Fidelity Extended Market Index Fu cut their holdings by 0.00% in the company over the course of the most recent quarter. It now holds a 0.13% position in Bionano Genomics Inc. thanks to 0.11 million shares amounting to $86842.0.